Atlas Trials

A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.

Clinical trial NCT04830644 · UNKNOWN

Trial details

NCT number
NCT04830644
Sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Primary Sjögren Syndrome
Start date
2021-03-22
Primary completion
2022-04-01
Enrollment
144

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.